CONMED Corporation (CNMD): Price and Financial Metrics
CONMED Corporation (CNMD)
Today's Latest Price: $74.62 USD
Updated Jun 2 6:40pm
Add CNMD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 132 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
CNMD Stock Summary
- CNMD's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 214.84 -- higher than 84.57% of US-listed equities with positive expected earnings growth.
- Conmed Corp's stock had its IPO on March 26, 1990, making it an older stock than 83.88% of US equities in our set.
- With a price/earnings ratio of 63.5, Conmed Corp P/E ratio is greater than that of about 89.78% of stocks in our set with positive earnings.
- Stocks that are quantitatively similar to CNMD, based on their financial statements, market capitalization, and price volatility, are GCP, LNN, CMD, EML, and NVT.
- CNMD's SEC filings can be seen here. And to visit Conmed Corp's official web site, go to www.conmed.com.
CNMD Stock Price Chart More Charts
CNMD Price/Volume Stats
| Current price | $74.62 | 52-week high | $116.81 |
| Prev. close | $73.94 | 52-week low | $37.66 |
| Day low | $73.73 | Volume | 211,300 |
| Day high | $74.98 | Avg. volume | 454,649 |
| 50-day MA | $65.86 | Dividend yield | 1.07% |
| 200-day MA | $92.67 | Market Cap | 2.13B |
CONMED Corporation (CNMD) Company Bio
CONMED Corporation is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The company was founded in 1970 and is based in Utica, New York.
CNMD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $74.62 | $30.79 | -58% |
We started the process of determining a valid price forecast for Conmed Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Conmed Corp ranked in the 26th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for CNMD, they are:
- Conmed Corp's weighted average cost of capital (WACC) is 8%; for context, that number is higher than 61.81% of tickers in our DCF set.
- CNMD's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 7%; for context, that number is higher than 61.81% of tickers in our DCF set.
- Relative to other stocks in its sector (Healthcare), Conmed Corp has a reliance on debt greater than 72.84% of them.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -59% |
| 1% | -58% |
| 2% | -58% |
| 3% | -58% |
| 4% | -57% |
| 5% | -57% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CNMD, try ABT, NUVA, ENTA, TMO, and BHC.
Loading social stream, please wait...